VentureBeat16d
Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium
In biochemical and cellular studies, Circle Pharma’s cyclin A/B RxL inhibitors have been shown ... Circle Pharma’s MXMO™ platform combines structure-based rational drug design and advanced ...
Nature3y
The classical and minimal models of cell cycle control
Cyclin-dependent kinases (CDKs) trigger the transition from G1 to S phase and from G2 to M phase by phosphorylating distinct sets of substrates. (B) CDK1 and CDK2 bind to multiple cyclins (cyclin ...
Medscape25d
Exendin-4 Stimulation of Cyclin A2 in B-Cell Proliferation
Kornfeld; Fredric E. Wondisford; Mehboob A. Hussain siRNA transfection achieved ∼40% knockdown of cyclin A2 protein(Fig. 5). This resulted in a significantly reduced Min6 proliferation rate (1. ...
Business Wire24d
Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors
About CID-078, Circle Pharma’s Cyclin A/B RxL Inhibitor Program CID-078 is ... Circle Pharma’s MXMO™ platform combines structure-based rational drug design and advanced synthetic chemistry ...